Drugs / AVI-4020
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00387283 | Oct → Dec 2006 | West Nile fever | Sarepta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00091845 | Nov 2004 | West Nile fever | Sarepta Therapeutics, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2011-05-06 | Sarepta Therapeutics, Inc. | Results Data From AVI BioPharma's RNA-Based Hemorrhagic Fever and Infectious Disease Programs to Be Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases sarepta.com ↗
The presentation, which will be given during the session called "New Antimicrobials: Preclinical and Clinical Studies," will feature data demonstrating the ability of a PMO, AVI-4020, to cross the blood-brain barrier in patients and rats with a neuroinvasive infectious disease suspected to be West Nile Virus. |
| 2006-11-10 | Sarepta Therapeutics, Inc. | Results AVI BioPharma Announces Positive Clinical Trial Results Delivering NEUGENE Antisense Drugs to the Central Nervous System sarepta.com ↗
AVI BioPharma, Inc. (Nasdaq:AVII), today announced human clinical trial results showing that three distinct NEUGENE(R) antisense drugs entered the cerebral spinal fluid (CSF) of healthy adult male volunteers following a single 100 mg dose via intravenous (IV) or subcutaneous (subq) injections. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-05-06 | Sarepta Therapeutics, Inc. | Data From AVI BioPharma's RNA-Based Hemorrhagic Fever and Infectious Disease Programs to Be Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases sarepta.com ↗ |
| 2006-11-10 | Sarepta Therapeutics, Inc. | AVI BioPharma Announces Positive Clinical Trial Results Delivering NEUGENE Antisense Drugs to the Central Nervous System sarepta.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVI-4020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00091845 ↗ |
| Action | Inhibit | “AVI-4020 was designed to interfere with West Nile virus translation” NCT00387283 ↗ |
| Modality | Oligonucleotide (other) | “AVI-4020 PMO drug” NCT00387283 ↗ |
| Route | Intravenous | “intravenously administered (IV) AVI-4020 Injection” NCT00091845 ↗ |